What is Traws Pharma?
Traws Pharma operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of novel oral small molecule therapies. The company's research focus is bifurcated into two critical therapeutic areas: respiratory viral infections and oncology. Its viral respiratory program features advanced candidates such as ratutrelvir, an oral inhibitor of the SARS-CoV-2 Mpro, and tivoxavir marboxil, an antiviral targeting influenza cap-dependent endonuclease. In the oncology space, the firm is developing narazaciclib, a proprietary multi-kinase CDK4-plus inhibitor designed to address resistance in refractory endometrial cancer and other solid tumors. By utilizing state-of-the-art drug development technology, Traws Pharma aims to mitigate the global burden of disease through safer, more effective therapeutic interventions.
How much funding has Traws Pharma raised?
Traws Pharma has raised a total of $72.6M across 1 funding round:
Other Financing Round
$72.6M
Other Financing Round (2024): $72.6M with participation from Tungsten Advisors
Key Investors in Traws Pharma
Tungsten Advisors
Tungsten Advisors is an investment banking firm specializing in strategic advisory and corporate finance for the healthcare and technology sectors, providing transactional services and direct investment support.
What's next for Traws Pharma?
Looking ahead, the strategic deployment of this recent financing will likely focus on the expansion of clinical trial operations and the optimization of manufacturing processes for its lead candidates. As the company transitions into more advanced stages of development, the focus will shift toward securing regulatory milestones and exploring potential licensing opportunities. The management team is expected to prioritize the progression of narazaciclib, given its potential to disrupt the current standard of care for patients with treatment-resistant solid tumors. Furthermore, the continued refinement of its antiviral portfolio will remain a core pillar of the company's long-term growth strategy, as it seeks to address persistent unmet medical needs in the global healthcare market.
See full Traws Pharma company page
